Table 3

Glycemic control during the antenatal and postpartum closed-loop feasibility phases±

Antenatal feasibilityPostnatal feasibility
28–32 weeks’ gestation32–36 weeks’ gestation>36 weeks’ gestation0–6 weeks
Participants (n)816912
Time in target range* (%)70.6 (64.2, 75.4)71.5 (68.9,75.9)72.3 (67.3, 80.3)77.1 (75.1, 90.4)
Time above target range (%)28.0 (23.0, 34.0)24.4 (22.8, 29.3)23.7 (17.7, 31.5)22.1 (9.5, 24.4)
Time below target range (%)1.9 (1.7, 2.3)2.0 (1.1, 3.9)2.3 (1.0, 3.0)2.4 (0.8, 3.7)
Mean glucose (mg/dL)124.2 (118.8, 129.6)120.6 (115.2, 124.2)118.8 (115.2, 124.2)138.6 (127.8, 147.6)
Sensor wear (h/day)22.4 (11.3, 23.2)19.9 (15.1, 23.0)NA16.5 (11.6, 19.2)
  • Data are median (IQR) unless otherwise indicated. NA, not applicable.

  • ±The antenatal closed-loop feasibility phase was from the end of the randomized crossover trial until delivery. The postnatal closed-loop feasibility phase was from delivery up to 6 weeks postpartum.

  • *The glucose target range was 63–140 mg/dL (3.5–7.8 mmol/L) during pregnancy and 70–180 mg/dL (3.9–10.0 mmol/L) after delivery.